Poison control centres across the United States are reporting a marked increase in semaglutide-related calls following FDA approval of the medication for weight management. However, new research reveals that the majority of these incidents stem from accidental dosing errors rather than intentional misuse—a finding that offers opportunity for intervention through targeted patient education.
The surge highlights a critical education gap that emerged as semaglutide transitioned from diabetes treatment to widespread weight-management use. Patients and prescribers alike have struggled to navigate the drug’s complex dose-titration schedule, leading to preventable overdose incidents. Healthcare providers and pharmacists are well-positioned to reduce these errors through structured counselling on weekly dosing intervals and proper injection technique.
According to the research, clear communication about dosing protocols could substantially mitigate preventable harm. The findings underscore the importance of comprehensive pharmacy counselling and written guidance to ensure safe medication use across the expanding patient population.
Read the full article on GMJ Newsroom.
Was this article helpful?
